Register today for ‘Looming threat’ or ‘Minor detail’? A free global health symposium on HIV drug resistance in Africa

Over the past 30 years, much progress has been made towards understanding and containing the worldwide HIV epidemic. People on antiretroviral therapy (ART) are living longer and new ‘Test and Treat’ approaches are reaching more people than ever. But an emerging global health crisis could threaten to reverse this progress.

The virus itself is increasingly becoming resistant to the very medications used to treat it. As a result, HIV drug resistance (HIVDR) has been reported in many countries around the globe and is affecting our most vulnerable populations. Recent WHO data indicate that in 12 out of 18 countries HIVDR has already surpassed a critical 10% mark. Particularly in Africa women are twice as likely to be resistant compared to men and resistance is also high in children under the age of 18 months. HIVDR compromises the $1/day ‘first line HIV treatment’. When patients need to shift to second line, treatment becomes two to three times more expensive and also more complex. Switching to 3rd line is hardly an option in the Africa reality due to very high costs and limited availability.

While there are new medications, such as Dolutegravir, that are less likely to create resistance, these are just starting to get implemented in Africa and there are many challenges to convert current programs to its use. In order to continue to make progress towards the UNAIDS target of ’90-90-90’[1], we need to address this issue much more actively.

Organized by the Amsterdam Institute for Global Health and Development and the Joep Lange Institute and facilitated by Prof. Tobias Rinke de Wit, the ‘Looming Threat or Minor Detail’ symposium brings together leading experts in the field to discuss  key insights into the drivers and development of HIVDR and its consequences for global HIV programs, with special emphasis on Africa.

Date:     November 11 from 1400-1700

Place:    Fonteijnzaal, Amsterdam, UMC (Location AMC)

Cost:      Free to attend

The event will also feature a presentation from one of the first people diagnosed with drug-resistant HIV and two AIGHD PhD candidates Cissy Kityo (Uganda) and Seth Inzaule (Kenya), who will defend their respective theses the following day. Spaces are limited so register today.

Program:

14:00 – 14:10: Introduction and welcome [Prof Tobias Rinke de Wit]

14:10 – 14:30: Igniting HIVDR in Uganda: a ‘looming threat’ for Africa? [Prof Peter Mugyenyi]

14:30 – 15:00: Is HIVDR important for Africa or just a ‘minor detail’? [Prof Francois Venter]

15.00 – 15:20: INSTI resistance, what will the future bring us? [Prof Charles Boucher]

15:20 – 15:40: HIVDR and the global threat of antimicrobial resistance [Prof Constance Schultsz]

15:40 – 15.50: The human face of HIVDR (‘say no to resistance’ video) [Moses Supercharger & Stigmaless Band]

15.50 – 16.00: What does HIVDR imply for the patient? [Moses Supercharger]

16.00 – 16:20: Latest WHO info on HIVDR; introducing Cissy & Seth contributions  [Dr. Silvia Bertagnolio]

16.20 – 16.40: Thesis summary PhD candidate [Cissy Kityo]

16:40 – 17.00: Thesis summary PhD candidate [Seth Inzaule]

17.00 – 17:05: Closure and drinks [Prof Tobias Rinke de Wit]

For more information, please email: info@aighd.org

[1] diagnosing 90% of those living with HIV, providing treatment to 90% of diagnosed people, and suppressing the virus in 90% of those on treatment